



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C., 20231.

Date:

12/26/07

By:

Valerie Jones

DOCKET NO.: 55325-8162.US00

RECEIVED
JAN 22 2001
FBI CENTER 1600/2900

#10
JLL
1/26/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Uster et al.

SERIAL NO.: 09/498,704

FILED: February 7, 2000

FOR: LIPOSOME COMPOSITION AND METHOD
FOR ADMINISTRATION OF A
RADIOSENSITIZER

EXAMINER: Kishore

ART UNIT: 1615

AMENDMENT UNDER 37 C.F.R. §1.111

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

This amendment is in response to the Office Action mailed September 27, 2001 in the above-identified application.

REMARKS

Reconsideration of the rejections set forth in the Office Action dated September 27, 2001 is respectfully requested.

I. Rejections Under 35 U.S.C. §103

Claims 1-30 were rejected under 35 U.S.C. §103 as being obvious over Martin et al., U.S. Patent No. 5,213,804 in view of Mori et al. (Cancer Chemother. Pharmacol., 35:447 (1995)).

Claims 1-30 were rejected under 35 U.S.C. §103 as being obvious over Martin et al. U.S. Patent No. 5,213,804 in view of Mori et al. further in view of Kassiss et al., U.S. Patent No. 5,077,034.

These rejections are respectfully traversed for the following reasons.